PLRX – pliant therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting [Yahoo! Finance]
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics (PLRX) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a "hold" rating on the stock.
Pliant Therapeutics (PLRX) had its "overweight" rating reaffirmed by Piper Sandler.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results [Yahoo! Finance]
Form S-8 PLIANT THERAPEUTICS,
Form 8-K PLIANT THERAPEUTICS, For: Mar 11
Form 10-K PLIANT THERAPEUTICS, For: Dec 31
Form 8-K PLIANT THERAPEUTICS, For: Mar 03
Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: Point72 Asset Management, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.